{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/prov/282316064"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/306257991" ] } },

    { "id" : "http://webisa.webdatacommons.org/306257991"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "These relate particularly to mode of action, safety and efficacy issues; with respect to the latter, questions such as optimal dose regimen, direct comparison with other biological agents and indicators for retreatment require appropriate answers.Table 6Summary of additional clinical and research aspects for future considerationConclusionAdditional data on rituximab in the management of RA have ac" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "pubmedcentralcanada.ca" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/255688901"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/306257991"] } } }
